



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 06-05-2009

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 17-04-2009 TO BE PUBLISHED 07-05-2009 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

304/2009	<b><u>13-04-2009</u></b> Imran Waheed Siddiqi, Karachi-Pakistan	“Wood preserve by fiberglass application”
305/2009	Star Syringe Limited, United Kingdom (Priority 22-04-2008 Great Britain)	“Syringes”
306/2009	Methanol Casale S.A., Switzerland (Priority 16-04-2008 Europe)	“Process for producing methanol from steam reforming”
307/2009	Eisai R&D Management Co., Ltd., Japan (Priority 15-04-2008 Japan)	“3-phenylpyrazolo[5,1-b]thiazole compounds”
308/2009	<b><u>14-04-2009</u></b> The Rockefeller University, USA	“Antibodies specific for the protofibril form of beta-amyloid protein”
309/2009	Unilever PLC, United Kingdom (Priority 28-04-2008 India)	“Disinfection composition and process”
310/2009	Bayer Schering Pharma Aktiengesellschaft, Germany (Priority 23-04-2008 Germany)	“Substituted hydropyrazolones and their use”
311/2009	Bayer Schering Pharma Aktiengesellschaft, Germany (Priority 22-04-2008 Europe)	“Substituted phenoxybenzamides”
312/2009	<b><u>15-04-2009</u></b> Sanofi-Aventis, France (Priority 17-04-2008 France)	“Combination of dronedarone with at least one diuretic, therapeutic application thereof”
313/2009	Schering Corporation, USA (Priority 15-04-2008 USA)	“High density compositions containing posaconazole and formulations comprising the same”
	<b><u>16-04-2009</u></b>	

314/2009	Boehringer Ingelheim International GmbH, Germany	“New compounds”
315/2009	Glaxo Group Limited, United Kingdom (Priority 18-04-2008 USA)	“Cathepsin C inhibitors”
316/2009	Glaxo Group Limited, United Kingdom (Priority 17-04-2008 Great Britain)	“Novel compounds”
317/2009	Glaxo Group Limited, United Kingdom (Priority 18-04-2008 USA)	“Cathepsin C inhibitors”
318/2009	Sanofi-Aventis, France (Priority 18-04-2008 USA)	“Use of dronedarone or a the pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood”
319/2009	Sanofi-Aventis, France (Priority 17-04-2008 France)	“Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality”
320/2009	<b><u>17-04-2009</u></b> Novozymes A/S, Denmark (Priority 17-04-2008 European)	“Laccase variants”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


929/2000 Pfizer Inc.,  
USA

“Pyrazolo[4,3-d]pyrimidin-7-one”

CO7D 231/16, A61K 31/519

**140063**

The present invention relates to a Compound of the formula (I):



(I)

Wherein

R<sup>1</sup> is -(CH<sub>2</sub>)<sub>n</sub>(C<sub>3</sub>-C<sub>5</sub>)cycloalkyl wherein n is 0,1,2 or 3; or R<sup>1</sup> is methyl, ethyl, iso-propyl; Cs cycloalkyl wherein n is 0, 1,2 or 3; or R<sup>1</sup> is methyl, ethyl, iso-propyl or n-propyl substituted by one or more C<sub>1</sub> to C<sub>4</sub> alkoxy substituents wherein said alkoxy substituent may be directly attached to any C-atom within the ethyl, iso-propyl or n-propyl groups; or R<sup>1</sup> is a C<sub>4</sub> alkyl group selected from i-, n-, sec- or t-

butyl optionally substituted by one or more substituents selected from C<sub>1</sub> to C<sub>4</sub> alkoxy or C<sub>3</sub> to C<sub>4</sub> cycloalkyl; R<sup>2</sup> is C<sub>1</sub> to C<sub>4</sub> alkyl; R<sup>13</sup> is OR<sup>3</sup> wherein R<sup>3</sup> is C<sub>1</sub> to C<sub>4</sub> alkyl optionally substituted with one or two C<sub>1</sub> to C<sub>4</sub> alkoxy substituents wherein said C<sub>1</sub> to C<sub>4</sub> alkyl and C<sub>1</sub> to C<sub>4</sub> alkoxy groups may optionally be terminated by a haloalkyl group such as CF<sub>3</sub>; R<sup>4</sup> is a piperazin-1-ylsulphonyl group having a single substituent, R<sub>10</sub> at the 4-position of the piperazinyl group and is optionally in the form of its 4-N-oxide and wherein R<sup>10</sup> is methyl or ethyl; are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

950/2001 Boehringer Ingelheim “New Inhalable powder containing tiotropium”  
Pharma GmbH & Co.,  
Kg,  
Germany A61K 31/439


**140064**

The invention relates to powdered preparations containing tiotropium for inhalation, as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

253/2003 Mitsubishi Tanabe “A benzofuran compound”  
Pharma Corporation,  
Japan CO7D 307/78

**140065**

The present invention provides a benzofuran derivative of the formula [1]:



wherein x is a group of the formula: -N= or -CH=; Y is an optionally substituted aminic group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R<sup>1</sup> is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R<sup>3</sup> is a hydrogen atom, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.


24/2005 Otsuka  
Pharmaceutical Co.,  
Limited,

“An amine salt of carbostyryl”

CO7D 215/237

**140066**

The invention provides an amine salt of a carbostyryl formed from a carbostyryl represented by the formula (1) [wherein R is a halogen atom; the substituted position of the side chain is 3- or 4-position in the carbostyryl skeleton; and the bonding between 3- and 4-positions of the carbostyryl skeleton is a single bond or a double bond] and an amine and the invention is useful as drugs for treating various diseases, especially as aqueous formulations due to the superior water solubility and the superior pharmacologic effects.




194/2005 Theravance, Inc.,  
USA

“Biphenyl-2-ylcarbamic acid 1-(2-[[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino]ethyl)piperidin-4-ylester useful as a muscuranic receptor antagonist”

CO7D 211/62

**140067**

This invention provides compound of formula I:



I

wherein a, b, c, m, n, s, t, n, d, p, W, Ar<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are as defined in the specification. The compound of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compound, process for preparing such compound and method of using such compound to treat pulmonary disorders.

658/2006 Honda Motor Co.,  
Ltd,  
Japan

“Improved float type engine oil level detection system”

FO1M 11/12

**140068**

An oil level detection apparatus having a float-type oil level detector (50) and a mode switching unit. The oil level detector emits a signal indicating that the oil level has dropped when a movable contact disposed on a float (54) makes contact with fixed contacts once the level of said oil (Lu) has dropped to a lower limit level. The mode switching unit switches between one of two modes selected from a first mode for actuating the alarm and stopping the engine (10) in accordance with the level drop signal, and a second mode for actuating the alarm and continuing to operate the engine (10) in accordance with the level drop signal.

714/2006 Pinter, S.A.,  
Spain

“Guide device for lapping yarns”

DO1H 13/06, DO2G 3/36

**140069**

The device comprises a set of separate, adjacent pivoting arms for each adjacent guide roller for lapping filaments, said arms being mounted with independent rotation capability and stable positioning at variable angles, on a support which is fixed adjustably on a single rail on which are also fixed the roving guides, also adjustably, said

support being connected to a fixed part of a spinning machine, by means of a resilient arm provided with flexion capability in a horizontal plane.

1085/2006 Cooltech  
Applications,  
France

“Thermal generator using magneto-calorific material”

F25B 21/01

**140070**

The present invention proposes a thermal generator which is non-polluting, has very-good energy efficiency, is of simple and economical design and uses little energy, at the same time as being capable of further development, flexible and modular. In this thermal generator (1), the thermal elements (3) composed of magneto-calorific material each comprises two separate collector circuits (31 and 32). a "hot" collector circuit connected to a hot heat transfer fluid circuit (5 I) and a "cold" collector circuit (32) linked to a cold heat transfer fluid circuit (52). The heat transfer fluid is made to move alternately in one or the other of the collector circuits (3 I and 32) depending on whether or not the thermal elements (3) are subjected to the magnetic field generated by the magnets (40) moving in rotation around a central axis (B) with respect to the thermal elements (3). The heat transfer fluid circuits (51 and 52) are partly incorporated in a plate (2) carrying the said thermal elements (3) and connected to external circuits which have heat exchangers (55 and 56) using the calories and frigories generated by those thermal elements (3). Applications: Heating, tempering, air conditioning or refrigeration in any industrial installation or any domestic application.

94/2007 Bilcare Limited,  
India

“A package-companion-user interactive system comprising a product package provided with a smart data processor and companion device”

A61J 01/03, A61J 07/04

**140071**

The present invention relates to a package-

companion-user interactive system providing a comprehensive means of product authentication, registration for effective compliance, with user real-time feedback. The system comprises of a product package provided with a smart data processor and companion device comprising a housing with package holding provision; an array of signal generating means and signal sensing means provided in the said device to receive and reflect signals generated by the said signal generating means; user interactive means; powered time tracking means; data decoding means, data processing data storage means, optionally equipped with audio visual display means, data transfer and connectivity means so configured to register user with the said device; authenticate product package register product package, and optionally carrying out transient data collection and/or user feed back; when the said product package is placed in the said housing; wherein the product package is without any severable conductor.

322/2007 Atlas Elektronik  
GmbH.,  
Bremen

“Method for finding the direction of sound-emitting targets using an electroacoustic receiving antenna”

G01S 3/808

**140072**

In a method for finding the direction of sound-emitting targets using an electroacoustic underwater receiving antenna, in-phase received signals are formed by application of time-delay coefficients to the received signals from the transducers, and are added to the latter to form array signals which indicate bearing directions defined by bearing angles. The levels of the array signals are recorded associated with the bearing angles, level maxima are detected in the level profile obtained in this way over the bearing angles, and bearing angles associated with the level maxima are emitted as target bearings. In order to suppress system-dependent bearing errors in the target bearings, a set of time-delay coefficients which are associated with the transducers is determined empirically and is stored for each carrier-related bearing angle by carrier-related direction finding of targets in the sea region which are located in bearing directions

which are scanned by known angle steps. The carrier-related bearing angles for finding the target bearing are calculated for north-related bearing angles using the heading of the antenna carrier, and the stored sets of time-delay coefficients which are associated with the calculated, carrier-related bearing angles are applied to the received signals.

577/2007 Dr. Fatima Bi,  
Seema Iqbal,  
Muhammad Arman,  
Mahmood-ul-Hassan,  
Muhammad Sadiq  
Ali,  
PCSIR, Karachi,  
Pakistan

“New formulation developed for emulsification of tenekil (Pesticide)

AO1N 65/00

**140073**

A new formulation is developed for tenekil, a pesticide used for the protection of crops like cotton, pepper, banana and sugar cane from nematodes, borers and termites etc. Product consists of 87.5% petkolin (active ingredient), 5.5% N-J, 4.5% unitox-4 and 2.5% xylene. In the present invention low cost emulsifiers like N-J and unitox-4 have been substituted in place of expensive emulsifiers i.e. triton-180 and triton-190 of previous tenekil formulation, it formed a thick, white and milky emulsion in water that remains stable for 24 hour. The efficacy of the product is statistically proved.


653/2007 Theravance Inc.,  
USA

“Pharmaceutically acceptable salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester useful as muscarinic receptor antagonists”

CO7D 211/62

**140074**

This invention provides pharmaceutically acceptable salt of compound of formula I:



wherein a, b, c, m, s, t, n, d, p, W, Ar<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>,

R<sup>4</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are as defined in the specification. The pharmaceutically acceptable salt of compound of formula I is muscarinic receptor antagonists. The invention also provides pharmaceutical composition containing such salt, process for preparing such salt and method of using such salt to treat pulmonary disorders.


969/2007 Novartis AG.,  
Switzerland

“Novel crystalline form of eptophilone B”

CO7D 333/06, CO7D 493/04, A61K 35/00

**140075**

The invention relates to new crystal modification C of eptophilone B



For use in treating warm-blooded animal suffering from a proliferative disease.

1370/2007 Mr. Mahmood Azam,  
Dr. Abid Hasnain,  
Mr. Muhammad  
Danish,  
Mr. Sohail Akhtar,  
Food Science and  
Technology,  
University of Karachi,  
Karachi, Pakistan

“Method of fractionating gliadin from wheat gluten protein and fabrication of edible film therefrom”

A23L 1/00 A61K 3/00

**140076**

A method for the development of biodegradable or edible film from wheat gluten protein has been revealed. For this purpose, a fraction of gliadin protein, on the basis of solubility, is recovered from ethanolic extract of wheat gluten protein to fabricate homogenous, transparent, heat sealable and water soluble edible films with novel functional and mechanical properties. To reduce film brittleness, glycerol was added in the formulation as a plasticizer. A three dimensional network of gliadin

protein's fraction, water and plasticizer is formed by virtue of new hydrogen bonds, hydrophobic interactions and disulphide bonds when such films are produced by casting technique followed by drying . This network provides resistance to moisture, lipid and gas permeation together with glossy sheen when coated on a variety of substrates.

### **SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139812	Glaxo Group Limited. United Kingdom	821/2002
139813	Novartis AG. Switzerland	1027/2002
139814	Sanofi-Aventis Deutschland GmbH. Germany	416/2003
139815	Sumitomo Chemical Company, Limited. Japan	191/2004
139816	Saudi Basic Industries Corporation, Saudi Arabia	1194/2005
139817	LS Cable Limited. Kirea	113/2006
139818	LS Cable Limited. Korea	114/2006
139819	Sumitomo Chemical Company, Limited. Japan	1115/2006
139820	Honda Motor Co., Limited. Japan	42/2007
139821	Technology Incubation Center, (NUST). Karachi, Pakistan	1265/2007

**(MRS. YASMEEN ABBASI)**  
CONTROLLER OF PATENTS  
Tel: 9215488